{"Title": ["Salesforce.com To Replace Allergan In S&P100", "Health Care Sector Update for 12/26/2019: HEXO,HEXO.TO,AGE,ACOR,SPPI", "Health Care Sector Update for 12/26/2019: AGE,ACOR,SPPI", "Health Care Sector Update for 12/23/2019: ACB,ACB.TO,SRPT,ACOR", "Health Care Sector Update for 10/04/2019: SDC,SRPT,ACOR,OVID", "Health Care Sector Update for 10/04/2019: SRPT,ACOR,OVID", "5 Top Gainers In Healthcare Sector (MNK, ENDP, MLNT...)", "Acorda Therapeutics (ACOR) Q2 2019 Earnings Call Transcript", "Salesforce.com To Replace Allergan In S&P100", "Validea Joseph Piotroski Strategy Daily Upgrade Report - 3/23/2019", "Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound?", "Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know", "Validea Joseph Piotroski Strategy Daily Upgrade Report - 2/21/2019", "Acorda Therapeutics Becomes Oversold", "Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates", "Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript", "Acorda Therapeutics (ACOR) Q1 2019 Earnings Call Transcript", "Array BioPharma (ARRY) Soars: Stock Adds 11% in Session", "Is Acorda Therapeutics (ACOR) Stock Outpacing Its Medical Peers This Year?", "Vertex Terminates COO Ian Smith on Code of Conduct Violation", "Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids", "Aerpio (ARPO) Jumps: Stock Rises 7.8%", "Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%", "ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study", "Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates", "Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect", "Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%", "Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%", "Company News For Dec 26, 2018", "Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal", "U.S. STOCKS ON THE MOVE-Oil stocks, bank stocks, Mindbody", "Health Care Sector Update for 12/24/2018: ACOR, CDXC, RDY, JNJ, PFE, MRK, ABT, AMGN", "Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher", "Why Mindbody, New Gold, and Acorda Therapeutics Jumped Today", "Health Care Sector Update for 12/24/2018: MB,ACOR,RDY", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 12/16/2018", "Here's Why Acorda Therapeutics Shares Sunk 15% Today", "Noteworthy Tuesday Option Activity: UAL, ALGN, ACOR", "Acorda Down More Than 30% in the Past 3 Months: Here's Why", "Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up", "Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija", "Acorda Therapeutics (ACOR) Q3 Earnings and Revenues Beat Estimates", "Centene's (CNC) Earnings and Revenues Top Estimates in Q3", "Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija", "Here's Why Acorda Therapeutics Is Falling by Double Digits Today", "Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down", "Oversold Conditions For Acorda Therapeutics", "ACOR Crosses Below Key Moving Average Level", "Acorda Therapeutics Inc (ACOR) Q3 2018 Earnings Conference Call Transcript", "What's Behind Acorda Therapeutics Crashing 24.5% Today", "Noteworthy Monday Option Activity: ALNY, ACOR, EROS", "Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates", "Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?", "Collaborations Help Alkermes Flip to Profitability", "RSI Alert: Acorda Therapeutics (ACOR) Now Oversold", "What's in Store for Cardinal Health (CAH) in Q4 Earnings?", "Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today", "Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?", "5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates", "Implied Volatility Surging for Acorda (ACOR) Stock Options", "Notable Friday Option Activity: ACOR, DE, HRTX", "Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher", "Here's Why Acorda Therapeutics Rose as Much as 30.3% Today", "Acorda (ACOR) Up 13.4% Since Earnings Report: Can It Continue?", "Is a Beat in Store for Vertex (VRTX) This Earnings Season?", "Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?", "5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates", "Implied Volatility Surging for Acorda (ACOR) Stock Options", "Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y", "New Strong Sell Stocks for April 18th", "After Hours Most Active for Feb 27, 2018 : ENDP, ACOR, INTC, SPPI, MDLZ, FRBK", "FDA Accepts Acorda's NDA for Parkinson's Disease Candidate", "Health Care Sector Update for 05/29/2018: AKER, ACOR, TTOO", "Health Care Sector Update for 05/29/2018: INSP,AKER,ACOR,TTOO", "Options Traders Expect Huge Moves in Acorda Therapeutics (ACOR) Stock", "Alkermes Submits NDA for Depression Candidate to the FDA", "Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%", "Stocks To Watch: Acorda Therapeutics Sees RS Rating Jump To 84", "Here's Why Acorda Therapeutics Inc. Stock Is Surging Today", "Health Care Sector Update for 01/19/2018: JNJ, PFE, ABT, MRK, AMGN, PAVM, ACOR, OBLN, AGIO, CHEK", "Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat", "Acorda Therapeutics Joins Rank Of Stocks With RS Ratings Over 90", "ACOR Crosses Above Key Moving Average Level", "Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija", "Parkinson's Space in Focus as Acorda Stops Tozadenant Trial", "Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks", "Acorda Stock Up Despite Phase III Trial on Tozadenant Stops", "Pre-Market Most Active for Jan 19, 2018 : ERIC, QQQ, TVIX, GE, IBM, SQ, NVDA, NOK, ACOR, GNC, WBK, USLV", "Acorda's Shares Down on Disappointing Ampyra View for 2018", "Mid-Day Market Update: YY Climbs After Strong Q3 Results; SandRidge Energy Shares Plummet", "Acorda Nose-Dives To 5-Month Low On Deaths In Parkinson's Studies", "Mid-Morning Market Update: Markets Open Lower; Target Profit Beats Estimates", "Health Care Sector Update for 11/15/2017: MLSS,APHB,ACOR", "Mid-Afternoon Market Update: OncoCyte Drops Following Q3 Results; Sorl Auto Parts Shares Jump", "Here's Why Acorda Therapeutics Got Crushed Today", "Health Care Sector Update for 11/20/2017: ACOR,ACST,ACST.V,ANTH", "Acorda Reports Death in Parkinson's Trials, Stock Down 40%", "Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y", "Allergan (AGN) to Report Q3 Earnings: What's in the Cards?", "Commit To Purchase Acorda Therapeutics At $17, Earn 15.6% Annualized Using Options", "Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi", "Acorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating", "Health Care Sector Update for 11/15/2017: ARA,APHB,ACOR", "Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update", "AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug", "FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down", "Mid-Day Market Update: Movado Rises After Strong Q2 Results; Finish Line Shares Slide", "Mid-Morning Market Update: Markets Open Lower; Best Buy Tops Q2 Estimates", "Pre-Market Most Active for Aug 29, 2017 : TVIX, BBY, FINL, QQQ, ACOR, XIV, ABCO, BAC, MYCC, SAP, BABA, GSK", "What Happened in the Stock Market Today", "Acorda Therapeutics Getting Closer To Key Technical Measure", "Health Care Sector Update for 08/29/2017: CTLT,JUNO,ACOR", "Why Acorda Therapeutics Is Losing One-Quarter of Its Value Today", "Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line", "Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More", "Acorda Files NDA for Parkinson's Disease Candidate Inbrija", "Wednesday 6/21 Insider Buying Report: ACOR, SBBX", "Health Care Sector Update for 08/29/2017: IMGN,JAZZ,JUNO,ACOR", "Mid-Afternoon Market Update: U.S. Stocks Turn Higher; J.Jill Shares Plummet", "Health Care Sector Update for 08/29/2017: CTLT,JUNO,ACOR", "Biogen's Fampyra Conditional Approval Converted to Standard", "Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss", "Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline", "Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug", "Monday's ETF Movers: GDXJ, VIOO", "Health Care Sector Update for 06/09/2017: ACOR", "Acorda Presents Phase III Data on PD Candidate CVT-301", "Why Is Acorda (ACOR) Down 8.4% Since the Last Earnings Report?", "Noteworthy Friday Option Activity: AMBA, ACOR, CC", "Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher", "Acorda Presents Data for Parkinson's Candidate CVT-301", "Why Is Acorda (ACOR) Up 10.6% Since the Last Earnings Report?", "Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge", "Why Acorda Therapeutics Inc Plummeted for a Second Straight Day", "Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today", "Acorda Therapeutics (ACOR) Jumps: Stock Adds 6.5% in Session", "Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options", "Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4", "Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data", "The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences", "Alkermes Starts Phase III Study to Treat Multiple Sclerosis", "Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?", "Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session", "Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?", "Why Acorda Therapeutics Stock Is Jumping Today", "Thursday's ETF Movers: XBI, GDX", "Teva (TEVA) Q4 Earnings: What's in Store for the Stock?", "Can Prothena (PRTA) Pull a Surprise This Earnings Season?", "Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?", "Can Humana (HUM) Pull a Surprise This Earnings Season?", "Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?", "GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?", "Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options", "Allergan (AGN) Q4 Earnings: What's in Store for the Stock?", "GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?", "The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma", "Notable Wednesday Option Activity: ACOR, AAP, SBAC", "Kura Oncology Starts Dosing Patients in Phase II CMML Study", "What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?", "Acorda Stops Post-Stroke Development Program on Ampyra", "Why Acorda Therapeutics Stock Is Slumping Today", "Mid-Day Market Update: Headwaters Surges On Acquisition News; Cubic Shares Slide", "Mid-Morning Market Update: Markets Open Higher; Symantec To Acquire Lifelock", "Health Care Sector Update for 11/21/2016: MNK,OGEN,ACOR", "Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?", "Kura Oncology Starts Dosing Patients in Phase II CMML Study", "Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y", "Oversold Conditions For Acorda Therapeutics", "Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News", "Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss", "Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade", "Health Care Sector Update for 11/21/2016: IMUC,OGEN,ACOR", "Health Care Sector Update for 08/26/2016: PTLA,TGTX,ACOR", "Notable Thursday Option Activity: ACOR, PG, SFL", "Notable Wednesday Option Activity: ACOR, SQ, AGN", "How The Parts Add Up: PBE Headed For $52", "Health Care Sector Update for 07/28/2016: JNJ, PFE, ABT, MRK, AMGN, ACOR, BMY", "Anavex's Lead Candidate Gets Orphan Drug Status Yet Again", "Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up", "Health Care Sector Update for 08/26/2016: ALR,ABT,TGTX,ACOR", "Health Care Sector Update for 08/26/2016: PTLA,TGTX,ACOR", "Notable Thursday Option Activity: ACOR, PG, SFL", "Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead", "Celldex (CLDX) Presents Phase II Melanoma Study Data", "The Medicines Co. Carbavance TANGO 1 Study Enrolled", "Alkermes Begins Phase I Study on Immuno-Oncology Drug", "First Week of August 19th Options Trading For Acorda Therapeutics (ACOR)", "Acorda Shelves Development of Epilepsy Treatment, Plumiaz", "Aegerion Enters into Settlement Agreement with DoJ and SEC", "Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More", "VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline", "Acorda (ACOR) Q1 Earnings Decline Y/Y, Ampyra in Focus", "Analysts See 10% Gains Ahead For The Holdings of IJT", "Seth Klarman Profits From Biotie Therapies Buyout", "Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well", "Acorda Gets Favorable Court Ruling in Ampyra Patent Lawsuit", "Why Petroleo Brasileiro SA Petrobras (ADR) (PBR), Acorda Therapeutics Inc (ACOR) and ArcelorMittal SA (ADR) (MT) Are 3 of Today\u2019s Worst Stocks", "Acorda Therapeutics' Stock Slumped in February: Is It Now a Bargain?", "Acorda Therapeutics (ACOR) Shares Cross Above 200 DMA", "IJT's Underlying Holdings Imply 20% Gain Potential", "Acorda Q4 Earnings Decline Y/Y, Ampyra & Pipeline in Focus", "Why Acorda Therapeutics (ACOR) Might Surprise This Earnings Season", "Why Acorda Therapeutics' Stock Sank 22.9% in March", "Acorda Gets Favorable Court Ruling in Ampyra Patent Lawsuit", "Why Petroleo Brasileiro SA Petrobras (ADR) (PBR), Acorda Therapeutics Inc (ACOR) and ArcelorMittal SA (ADR) (MT) Are 3 of Today\u2019s Worst Stocks", "Acorda Therapeutics' Stock Slumped in February: Is It Now a Bargain?", "Acorda Therapeutics (ACOR) Shares Cross Above 200 DMA", "IJT's Underlying Holdings Imply 20% Gain Potential", "Will Lilly (LLY) Keep the Earnings Streak Alive in Q4?", "Allergan's Botox Gains FDA Nod for Lower Limb Spasticity", "Will Teva (TEVA) Continue with its Earnings Streak in Q4?", "Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?", "What Makes Incyte (INCY) a Strong Sell?", "Biotie Therapies (BITI) Catches Eye: Stock Moves Up 86.5%", "J&J Plans to Cut 3,000 Medical Devices Jobs, 2015 View Intact", "Biotie Therapies Soars on $363M Buyout Deal with Acorda", "Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie", "Mid-Day Market Update: Dow Surges 150 Points; Progressive Waste Shares Spike Higher", "Will Biogen (BIIB) Beat 4Q Earnings on MS Franchise Sales?", "Closing Update: Dow, S&P 500 Hang On For Narrow Gains; Nasdaq Struggles as Energy, Mining Stocks Slump", "Eleven Biotherapeutics' Eye Drug Fails in Phase III Study", "Health Care Sector Update for 01/19/2016: BITI,ACOR,AEZS,AEZ.TO,EBIO", "Mid-Afternoon Market Update: US Stocks Turn Red; Crude Oil Falls Over 3%", "Sarepta Tanks, Eteplirsen Briefing Document Raises Concerns", "Is Acorda Therapeutics (ACOR) a Great Growth Stock?", "Vertex Pharmaceuticals (VRTX) Jumps: Stock Moves Up 5.8%", "Here's Why Biotie Therapies Corp.'s Stock Skyrocketed Today", "New Strong Buy Stocks for January 13th", "Sangamo Biosciences (SGMO) Worth a Look: Stock Up 9.2%", "Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus", "Acorda's Ampyra Ends 2015 on Strong Note, Pipeline in Focus", "Health Care Sector Update for 12/03/2015: FOMX, ACOR, PSTI", "Bristol-Myers' Opdivo Gets Priority Review from the FDA", "Why Acorda Therapeutics (ACOR) Could Be Positioned for a Surge?", "Geron Up, Myelodysplastic Syndromes Phase II/III Study Begins", "Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View", "Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus", "Acorda Therapeutics Breaks Above 200-Day Moving Average - Bullish for ACOR", "The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie", "Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay", "Acorda Therapeutics (ACOR) Jumps: Stock Moves Up 12%", "Acorda Soars, Settles Ampyra Patent Dispute with Allergan", "Looking for a Top Momentum Stock? 3 Reasons Why Acorda Therapeutics (ACOR) is a Great Choice", "After Hours Most Active for Oct 1, 2015 : HLX, MU, CAA, RMBS, QQQ, ETE, SUNE, MSFT, ACOR, CSCO, PFE, RAD", "3 Biotech Stocks Bucking the Stock Market Crash", "The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure", "Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher", "Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data", "Why Acorda Therapeutics, Inc. Stock Surged Higher Today", "Mid-Morning Market Update: Markets Open Higher; Best Buy Tops Q2 Views", "Why Acorda Therapeutics Is Soaring 12% Today", "After Hours Most Active for Oct 1, 2015 : HLX, MU, CAA, RMBS, QQQ, ETE, SUNE, MSFT, ACOR, CSCO, PFE, RAD", "Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog", "Did Researchers Just Unlock the Secret to Fighting Parkinson's Disease?", "8 Biotech Stocks to Buy", "ACOR Crosses Above Key Moving Average Level", "Bayer Files Hemophilia A Drug Marketing Application in Japan - Analyst Blog", "AMAG Down on Cord Blood Registry Deal for $700 Million - Analyst Blog", "Acorda (ACOR) Gets Favorable Outcome in Ampyra IPR Issue", "Alexion's Strensiq and Kanuma Get Positive CHMP Opinions - Analyst Blog", "Bristol-Myers Announces Job Cuts, Changes in R&D Sites - Analyst Blog", "Catalyst Pharmaceuticals Reports Tourette's Disorder Data - Analyst Blog", "Bayer Contraceptive Essure to Face FDA Panel on Complaints - Analyst Blog", "McKesson Keeps FY16 Earnings View, Acquisitions Hold Key - Analyst Blog", "Synta Reports Encouraging Preclinical Data on Ganetespib - Analyst Blog", "Vanda Pharmaceuticals' Schizophrenia Drug Shows Success - Analyst Blog", "Regeneron/Bayer's Eylea Gets Label Expansion in Japan - Analyst Blog", "Vical's Genital Herpes Vaccine Fails in Phase I/II Study - Analyst Blog", "Isis Pharmaceuticals Up on Spinal Muscular Atrophy Data - Analyst Blog", "Epizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog", "Bullish Two Hundred Day Moving Average Cross - ACOR", "Acorda Gains on Positive Parkinson's Disease Study Data - Analyst Blog", "Bayer (BAYRY) Up on Deal to Sell Diabetes Care Business - Analyst Blog", "Novo Nordisk Reveals New Findings from Additional Studies - Analyst Blog", "Acorda Therapeutics (ACOR) Shares March Higher, Can It Continue? - Tale of the Tape", "Gilead Reveals Encouraging Data from Leukemia Study - Analyst Blog", "Aegerion's Juxtapid Successful in Phase III Japanese Study - Analyst Blog", "Actavis to Continue Selling Namenda IR under Court Ruling - Analyst Blog", "XBiotech's Xilonix Recommended for Colorectal Cancer Study - Analyst Blog", "Alnylam Files Clinical Trial Application for ALN-AAT - Analyst Blog", "Parkinson's biotech Cynapsus Therapeutics files for a $60 million US IPO", "Teva Presents Encouraging Data from Chronic Migraine Study - Analyst Blog", "Ultragenyx KRN23 Positive in Children, to be Studied in Adults - Analyst Blog", "Sanofi (SNY) Exercises Celiac Disease Program Option - Analyst Blog", "Inovio Narrows Q1 Loss Y/Y, Misses Earnings Estimates - Analyst Blog", "Acorda Posts 1Q Loss, Ampyra Generic Challenges in Focus - Analyst Blog", "Will United Therapeutics (UTHR) Miss This Earnings Season? - Analyst Blog", "Will Hospira (HSP) Earnings Surprise Estimates in Q1? - Analyst Blog", "Will Bristol-Myers (BMY) Earnings Streak Continue in Q1? - Analyst Blog", "Acorda Reports Encouraging Data on MS Drug - Analyst Blog", "Eli Lilly, Sanford-Burnham Ink Deal for Immunotherapies - Analyst Blog", "Sanofi (SNY) Exercises Celiac Disease Program Option - Analyst Blog", "Inovio Narrows Q1 Loss Y/Y, Misses Earnings Estimates - Analyst Blog", "Acorda Posts 1Q Loss, Ampyra Generic Challenges in Focus - Analyst Blog", "Will United Therapeutics (UTHR) Miss This Earnings Season? - Analyst Blog", "Will Hospira (HSP) Earnings Surprise Estimates in Q1? - Analyst Blog", "Will Bristol-Myers (BMY) Earnings Streak Continue in Q1? - Analyst Blog", "Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog", "This New Hedge Fund Strategy Just Might Be Crazy Enough To Work", "Ocular Therapeutix Slumps 19% after Negative Study Data - Analyst Blog", "Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog", "Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog", "Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog", "Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog", "Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog", "Cambrex (CBM) Looks Good: Stock Adds 11.6% in Session - Tale of the Tape", "Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog", "What Makes Novavax (NVAX) a Strong Sell? - Tale of the Tape", "BioDelivery Sciences International (BDSI) Crumbles: Stock Falls 24.3% - Tale of the Tape", "Amgen's Kyprolis Gets FDA Priority Review for Expanded Use - Analyst Blog", "Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the Tape", "Proteon Up on Positive Long-Term Data on its Candidate - Analyst Blog", "Avalanche Biotechnologies (AAVL) Crumbles: Stock Falls by 6.4% - Tale of the Tape", "Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog", "Raptor Pharmaceuticals (RPTP) in Focus: Stock Falls 9.7% - Tale of the Tape", "Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog", "The Zacks Analyst Blog Highlights: HSBC Holdings, Goldman Sachs, Acorda Therapeutics, Biogen Idec and Ross Stores - Press Releases", "OvaScience, Inc. (OVAS) in Focus: Stock Surges 12.2% - Tale of the Tape", "Coronado Biosciences, Inc. (CNDO) in Focus: Stock Jumps 8.6% - Tale of the Tape", "Weakness Seen in Five Prime Therapeutics (FPRX) Estimates: Should You Stay Away? - Tale of the Tape", "2 Stocks to Beat the Dollar's Volatile Run - Analyst Blog", "Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - Analyst Blog", "Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog", "Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog", "The Zacks Analyst Blog Highlights: HSBC Holdings, Goldman Sachs, Acorda Therapeutics, Biogen Idec and Ross Stores - Press Releases", "OvaScience, Inc. (OVAS) in Focus: Stock Surges 12.2% - Tale of the Tape", "Coronado Biosciences, Inc. (CNDO) in Focus: Stock Jumps 8.6% - Tale of the Tape", "Weakness Seen in Five Prime Therapeutics (FPRX) Estimates: Should You Stay Away? - Tale of the Tape", "2 Stocks to Beat the Dollar's Volatile Run - Analyst Blog", "Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog", "Aeterna Zentaris Inc. (AEZS) in Focus: Stock Jumps 5.3% - Tale of the Tape", "Amicus Therapeutics Slumps: FOLD Falls 6.8% in Session - Tale of the Tape", "Dicerna Pharmaceuticals (DRNA) Crumbles: Stock Falls by 6.4% - Tale of the Tape", "Biogen Gains on Positive Alzheimer's Drug Interim Results - Analyst Blog", "Celgene Presents Efficacy, Safety Data on Otezla - Analyst Blog", "Pfizer Reveals Detailed Xeljanz Data from Psoriasis Study - Analyst Blog", "Inovio Pharmaceuticals, Inc. (INO) Jumps: Stock Rises 12.8% - Tale of the Tape", "Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog", "Aeterna Zentaris Inc. (AEZS) in Focus: Stock Jumps 5.3% - Tale of the Tape", "Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog", "Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog", "Merck's Sugammadex Faces Setback, FDA Delays Meeting - Analyst Blog", "Alnylam Announces Positive Data from Natural History Study - Analyst Blog", "TrovaGene (TROV) Posts Wider Q4 Loss on Higher Expenses - Analyst Blog", "Geron Corporation (GERN) Jumps: Stock Rises 5.6% - Tale of the Tape", "Zacks Rank #1 Additions for Thursday - Tale of the Tape", "Eleven Biotherapeutics (EBIO) Crumbles: Stock Falls by 5.6% - Tale of the Tape", "Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog", "Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog", "Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog", "Acorda Therapeutics (ACOR) Tumbles: Stock Goes Down 9.7% - Tale of the Tape", "Will Hospira (HSP) Miss Q4 Earnings on Low Precedex Sales? - Analyst Blog", "Why Earnings Season Could Be Great for Acorda Therapeutics (ACOR) - Tale of the Tape", "Relative Strength Alert For Acorda Therapeutics", "Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog", "Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog", "Will Zoetis (ZTS) Earnings Disappoint Expectation in Q4? - Analyst Blog", "Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog", "Will Teva (TEVA) Earnings Surprise on Higher Sales? - Analyst Blog", "Will Glaxo (GSK) Q4 Earnings Suffer from Lower Revenues? - Analyst Blog", "Will Gilead (GILD) Miss Q4 Earnings on Low HCV Drug Sales? - Analyst Blog", "DaVita Healthcare (DVA): What's in Store for Q4 Earnings? - Analyst Blog", "Will Merck's (MRK) Q4 Earnings be Hit by Patent Expiries? - Analyst Blog", "Will Generics Continue to Hit Eli Lilly's (LLY) Q4 Earnings? - Analyst Blog", "Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog", "Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog", "Will Vertex (VRTX) Surprise with a Lower Loss in Q4? - Analyst Blog", "First Week of March 20th Options Trading For Acorda Therapeutics (ACOR)", "Closing Update: Late Bounce Carries Stocks to Second Positive Day in a Row; Tech Shares Pace Advance", "Will Allergan (AGN) Disappoint on Earnings This Quarter? - Analyst Blog", "Strength Seen in Alliqua (ALQA): Stock Up 13.2% in Session - Tale of the Tape", "Zacks Rank #1 Additions for Tuesday - Tale of the Tape", "AMAG, Takeda Mutually End Agreement for Feraheme - Analyst Blog", "BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog", "Cyberonics: VNS Therapy Strong, Reimbursement Woes Stay - Analyst Blog", "Qiagen Poised on Molecular Diagnostics, International Strength - Analyst Blog", "3 Companies Growing Faster Than MannKind Corporation", "Health Care Sector Update for 01/20/2015: VBLT,ACOR,BLRX,PETS,MDWD", "Is Acorda Therapeutics (ACOR) Stock a Solid Choice Right Now? - Tale of the Tape", "ACOR Crosses Below Key Moving Average Level", "Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog", "Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog", "5 Best Biotech Stocks to Buy Now", "Acorda Skyrockets on $525M Civitas Therapeutics Deal - Analyst Blog", "ACOR Makes Bullish Cross Above Critical Moving Average", "Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit - Analyst Blog", "Sector Update: Health Care", "Sector Update: Health-Care Shares Flat Pre-Market", "Pre-Market Most Active for Sep 24, 2014 : AAPL, GSK, MACK, AVNR, SAN, BABA, ACOR, SIRI, TVIX, NOK, BAC, AZN", "Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results", "Wednesday Sector Leaders: Drugs, Biotechnology Stocks", "Wednesday's ETF Movers: XBI, GDXJ", "U.S. Stocks Rise; Accenture Shares Decline On Weak Forecast", "Markets Edge Lower; KB Home Posts Downbeat Results", "Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog", "Will Teva Pharmaceutical (TEVA) Beat Q2 Earnings Estimates? - Analyst Blog", "Healthcare Spending Uptrend: 3 Medical Stocks for Strong Growth - Analyst Blog", "Markets Edge Higher; Alcoa Profit Beats Street View", "Sector Update: Healthcare Shares Flat Pre-Market; Acorda Could File Patent Infringement Suit", "Sector Update: Healthcare", "ACOR Makes Notable Cross Below Critical Moving Average", "Bullish Two Hundred Day Moving Average Cross - ACOR", "Sector Update: Healthcare", "Acorda Therapeutics (ACOR) in Focus: Stock Tumbles 9% - Tale of the Tape", "Sector Update: Healthcare Shares Flat Pre-Market; Pfizer Teams with Cellectis on Immunotherapy", "Mid-Day Market Update: Amira Rises On Upbeat Earnings; Acorda Therapeutics Shares Tumble", "Mid-Morning Market Update: Markets Gain; FactSet Posts Rise In Revenue", "Mid-Afternoon Market Update: Oil Falls, US Indexes Rise In Afternoon Session", "First Week of January 2015 Options Trading For Acorda Therapeutics (ACOR)", "Acorda Therapeutics (ACOR) in Focus: Stock Moves 7.8% Higher - Tale of the Tape", "Acorda Down on Plumiaz CRL - Analyst Blog", "Next Chapter In The Acorda Story Will Be A Page Turner", "Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape", "Acorda Up After Q4 Earnings - Analyst Blog", "Sector Update: Healthcare", "Sector Update: Healthcare Shares Fairly Flat; Acorda Q4 Earnings Top Street View", "Will Zoetis (ZTS) Miss Estimates in Q4? - Analyst Blog", "Acorda Misses on Earnings, Beats Revs - Analyst Blog", "ACOR Preliminary Q4 Revs Look Good - Analyst Blog", "Positive Data on Incyte's Jakafi - Analyst Blog", "Another R&D Failure for Eli Lilly - Analyst Blog", "MDCO Acquires Rempex - Analyst Blog", "BioDelivery Sciences (BDSI) in Focus: Stock Adds 10.9% in Session - Tale of the Tape", "Biogen's Hemophilia B Drug Approval Delayed - Analyst Blog", "Dendreon Narrows Loss, Provenge Disappoints Again - Analyst Blog", "Acorda Therapeutics, Inc. (ACOR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Acorda Down on Q3 Earnings - Analyst Blog", "Acorda's Label Expansion Efforts - Analyst Blog", "Acorda's GGF2 in Another Study - Analyst Blog", "Biotech Stocks Continue Recent Downtrend; Ariad Tumbles to Lowest Price in Nearly Three Years", "Acorda Progresses with Pipeline - Analyst Blog", "Acorda Misses on Earnings by a Penny - Analyst Blog", "Acorda Expands Pipeline - Analyst Blog", "Chelsea Therapeutics (CHTP) Worth Watching: Stock Surges 11% - Tale of the Tape", "Acorda Down on Q3 Earnings - Analyst Blog", "Acorda's Label Expansion Efforts - Analyst Blog", "Acorda's GGF2 in Another Study - Analyst Blog", "Biotech Stocks Continue Recent Downtrend; Ariad Tumbles to Lowest Price in Nearly Three Years", "Biotech Alkermes Poised To Swell On Pipeline Wins", "Market Wrap for Tuesday, April 16: Stock Market Rebounds Strongly From Monday's Sharp Losses", "Mid-Afternoon Market Update: Explosions Rock Downtown Boston, Authorities Unsure if Explosive Devices", "Data on Acorda Pipeline Candidate - Analyst Blog", "Acorda Reports Data on Epilepsy Drug - Analyst Blog", "Acorda Presents GGF2 Data - Analyst Blog", "Earnings Miss at Acorda - Analyst Blog", "Zacks Rank #5 Additions for Thursday - Tale of the Tape", "Acorda Presents Encouraging Data - Analyst Blog", "Acorda Gets US Army Support - Analyst Blog", "Zacks Rank #5 Additions for Wednesday - Tale of the Tape", "Mid-Day Market Update: Sprint Surges On Dish Network Offer, AuRico Gold Tumbles", "Acorda Reports Data on Epilepsy Drug - Analyst Blog", "Acorda Completes Acquisition of Neuronex - Analyst Blog", "Celgene, Sutro Join Forces - Analyst Blog", "Alkermes Reverts to Neutral - Analyst Blog", "Acorda Beats on All Fronts - Analyst Blog", "Acorda's Ampyra Patent Extended - Analyst Blog", "Acorda Initiated at Neutral - Analyst Blog", "Alkermes Maintains Fiscal 2013 View - Analyst Blog", "Acorda Provides Guidance - Analyst Blog", "Acorda Completes Acquisition of Neuronex - Analyst Blog", "Celgene, Sutro Join Forces - Analyst Blog", "Pre-Market Earnings Report for July 31, 2012 : BP, ADM, AET, AMG, WTR, BRKR, AVX, AUXL, ACOR, ALLT, CPLP, ABFS", "Acorda Commences Patient Enrollment - Analyst Blog", "Revenues Climb at Acorda - Analyst Blog", "Zacks #1 Rank Additions for Tuesday - Tale of the Tape", "After Hours Most Active for Oct 4, 2012 : SUN, PETM, AMAT, QQQ, CAB, ACOR, NVDA, BAC, ORCL, A, NOK, HPQ", "Back to Neutral on Alkermes - Analyst Blog", "Acorda Reports Data on Ampyra study - Analyst Blog", "Top 10 list of unusual option activity", "Brain Disorders: 3 Biotech Stocks at the Forefront", "Options Ideas: 24 Healthcare Stocks With Bullish Options Sentiment", "Put sellers show confidence in Acorda", "How To Play Biotech With ETFs", "Biogen's Fampyra Launched in Canada - Analyst Blog", "The Top 20 Most Undervalued Healthcare Stocks By Target Price"], "Elapsed Time": ["MAY 6, 2020", "DEC 26, 2019", "DEC 26, 2019", "DEC 23, 2019", "OCT 4, 2019", "OCT 4, 2019", "SEP 10, 2019", "AUG 2, 2019", "MAY 6, 2020", "MAR 23, 2019", "MAR 16, 2019", "MAR 15, 2019", "FEB 21, 2019", "FEB 20, 2019", "FEB 15, 2019", "FEB 15, 2019", "MAY 4, 2019", "FEB 6, 2019", "JAN 31, 2019", "JAN 24, 2019", "JAN 22, 2019", "JAN 22, 2019", "JAN 15, 2019", "JAN 14, 2019", "FEB 14, 2019", "JAN 10, 2019", "JAN 9, 2019", "JAN 7, 2019", "DEC 26, 2018", "DEC 26, 2018", "DEC 24, 2018", "DEC 24, 2018", "JAN 14, 2019", "DEC 24, 2018", "DEC 24, 2018", "DEC 16, 2018", "DEC 11, 2018", "DEC 4, 2018", "NOV 15, 2018", "NOV 1, 2018", "DEC 24, 2018", "OCT 31, 2018", "OCT 23, 2018", "SEP 14, 2018", "SEP 13, 2018", "SEP 11, 2018", "SEP 10, 2018", "SEP 10, 2018", "OCT 31, 2018", "SEP 10, 2018", "SEP 10, 2018", "AUG 3, 2018", "AUG 3, 2018", "JUL 27, 2018", "JUL 25, 2018", "JUL 24, 2018", "SEP 10, 2018", "JUL 20, 2018", "JUL 19, 2018", "JUN 25, 2018", "JUN 22, 2018", "JUN 11, 2018", "JUN 8, 2018", "JUN 1, 2018", "JUL 23, 2018", "JUL 20, 2018", "JUL 19, 2018", "MAY 24, 2018", "MAY 3, 2018", "APR 18, 2018", "FEB 27, 2018", "FEB 21, 2018", "MAY 29, 2018", "MAY 29, 2018", "FEB 6, 2018", "FEB 1, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 19, 2018", "JAN 19, 2018", "FEB 16, 2018", "FEB 15, 2018", "DEC 13, 2017", "DEC 8, 2017", "NOV 22, 2017", "NOV 22, 2017", "NOV 21, 2017", "JAN 19, 2018", "NOV 16, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 20, 2017", "NOV 16, 2017", "NOV 1, 2017", "OCT 26, 2017", "OCT 23, 2017", "OCT 19, 2017", "OCT 3, 2017", "NOV 15, 2017", "AUG 31, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "SEP 26, 2017", "AUG 29, 2017", "AUG 29, 2017", "JUL 28, 2017", "JUL 5, 2017", "JUN 30, 2017", "JUN 21, 2017", "AUG 29, 2017", "AUG 29, 2017", "JUN 1, 2017", "MAY 25, 2017", "APR 28, 2017", "APR 6, 2017", "APR 5, 2017", "APR 3, 2017", "JUN 9, 2017", "JUN 7, 2017", "JUN 1, 2017", "MAR 31, 2017", "MAR 31, 2017", "MAR 30, 2017", "MAR 17, 2017", "APR 3, 2017", "APR 3, 2017", "MAR 31, 2017", "MAR 10, 2017", "FEB 23, 2017", "FEB 15, 2017", "FEB 15, 2017", "FEB 14, 2017", "MAR 17, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 10, 2017", "FEB 6, 2017", "FEB 3, 2017", "FEB 2, 2017", "FEB 2, 2017", "FEB 2, 2017", "FEB 2, 2017", "JAN 25, 2017", "FEB 8, 2017", "JAN 18, 2017", "JAN 17, 2017", "NOV 22, 2016", "NOV 21, 2016", "NOV 21, 2016", "NOV 21, 2016", "NOV 21, 2016", "JAN 24, 2017", "JAN 18, 2017", "OCT 28, 2016", "OCT 27, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 26, 2016", "NOV 21, 2016", "AUG 26, 2016", "AUG 25, 2016", "AUG 3, 2016", "AUG 2, 2016", "JUL 28, 2016", "JUN 23, 2016", "JUN 21, 2016", "AUG 26, 2016", "AUG 26, 2016", "AUG 25, 2016", "JUN 8, 2016", "JUN 6, 2016", "MAY 27, 2016", "MAY 26, 2016", "JUN 21, 2016", "MAY 23, 2016", "MAY 13, 2016", "MAY 10, 2016", "MAY 4, 2016", "APR 29, 2016", "APR 26, 2016", "APR 15, 2016", "MAY 25, 2016", "MAR 22, 2016", "MAR 14, 2016", "MAR 14, 2016", "MAR 2, 2016", "FEB 22, 2016", "FEB 12, 2016", "FEB 10, 2016", "APR 12, 2016", "MAR 22, 2016", "MAR 14, 2016", "MAR 14, 2016", "MAR 2, 2016", "FEB 22, 2016", "JAN 26, 2016", "JAN 26, 2016", "FEB 10, 2016", "JAN 25, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 19, 2016", "JAN 25, 2016", "JAN 19, 2016", "JAN 19, 2016", "JAN 19, 2016", "JAN 19, 2016", "JAN 18, 2016", "JAN 15, 2016", "JAN 15, 2016", "JAN 19, 2016", "JAN 13, 2016", "JAN 13, 2016", "JAN 13, 2016", "JAN 12, 2016", "DEC 3, 2015", "NOV 17, 2015", "NOV 6, 2015", "JAN 15, 2016", "OCT 29, 2015", "OCT 23, 2015", "OCT 22, 2015", "OCT 8, 2015", "OCT 7, 2015", "OCT 6, 2015", "OCT 6, 2015", "NOV 2, 2015", "OCT 1, 2015", "AUG 28, 2015", "AUG 27, 2015", "AUG 26, 2015", "AUG 26, 2015", "AUG 25, 2015", "AUG 25, 2015", "OCT 5, 2015", "OCT 1, 2015", "JUL 31, 2015", "JUL 18, 2015", "JUL 16, 2015", "JUL 14, 2015", "JUL 1, 2015", "JUN 30, 2015", "AUG 25, 2015", "JUN 29, 2015", "JUN 26, 2015", "JUN 25, 2015", "JUN 25, 2015", "JUN 25, 2015", "JUN 24, 2015", "JUN 24, 2015", "JUN 29, 2015", "JUN 23, 2015", "JUN 23, 2015", "JUN 22, 2015", "JUN 22, 2015", "JUN 17, 2015", "JUN 11, 2015", "JUN 8, 2015", "JUN 23, 2015", "JUN 1, 2015", "MAY 27, 2015", "MAY 26, 2015", "MAY 19, 2015", "MAY 18, 2015", "MAY 16, 2015", "MAY 15, 2015", "JUN 3, 2015", "MAY 14, 2015", "MAY 12, 2015", "MAY 4, 2015", "APR 27, 2015", "APR 27, 2015", "APR 27, 2015", "APR 23, 2015", "MAY 15, 2015", "MAY 14, 2015", "MAY 12, 2015", "MAY 4, 2015", "APR 27, 2015", "APR 27, 2015", "APR 27, 2015", "APR 13, 2015", "APR 19, 2015", "APR 8, 2015", "APR 8, 2015", "APR 7, 2015", "APR 7, 2015", "APR 6, 2015", "APR 2, 2015", "APR 1, 2015", "APR 8, 2015", "MAR 31, 2015", "MAR 31, 2015", "MAR 31, 2015", "MAR 30, 2015", "MAR 30, 2015", "MAR 27, 2015", "MAR 27, 2015", "APR 1, 2015", "MAR 26, 2015", "MAR 25, 2015", "MAR 25, 2015", "MAR 25, 2015", "MAR 25, 2015", "MAR 24, 2015", "MAR 24, 2015", "MAR 26, 2015", "MAR 26, 2015", "MAR 25, 2015", "MAR 25, 2015", "MAR 25, 2015", "MAR 25, 2015", "MAR 24, 2015", "MAR 20, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 19, 2015", "MAR 18, 2015", "MAR 16, 2015", "MAR 16, 2015", "MAR 16, 2015", "MAR 13, 2015", "MAR 13, 2015", "MAR 12, 2015", "MAR 17, 2015", "MAR 16, 2015", "MAR 16, 2015", "FEB 11, 2015", "FEB 11, 2015", "FEB 10, 2015", "FEB 10, 2015", "FEB 27, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 2, 2015", "FEB 2, 2015", "FEB 10, 2015", "FEB 2, 2015", "JAN 29, 2015", "JAN 28, 2015", "JAN 27, 2015", "JAN 27, 2015", "JAN 23, 2015", "JAN 20, 2015", "FEB 2, 2015", "DEC 30, 2014", "DEC 30, 2014", "DEC 30, 2014", "DEC 30, 2014", "DEC 30, 2014", "DEC 30, 2014", "DEC 17, 2014", "JAN 20, 2015", "DEC 1, 2014", "NOV 14, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 21, 2014", "SEP 25, 2014", "SEP 24, 2014", "DEC 16, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "AUG 4, 2014", "JUL 30, 2014", "JUL 23, 2014", "JUL 9, 2014", "JUN 26, 2014", "JUN 26, 2014", "JUN 25, 2014", "AUG 26, 2014", "JUN 18, 2014", "JUN 18, 2014", "JUN 18, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "MAY 20, 2014", "JUN 19, 2014", "MAY 5, 2014", "APR 10, 2014", "MAR 5, 2014", "FEB 18, 2014", "FEB 13, 2014", "FEB 13, 2014", "FEB 10, 2014", "MAY 7, 2014", "JAN 14, 2014", "DEC 10, 2013", "DEC 6, 2013", "DEC 5, 2013", "DEC 4, 2013", "DEC 3, 2013", "NOV 15, 2013", "JAN 17, 2014", "NOV 4, 2013", "OCT 16, 2013", "OCT 14, 2013", "OCT 9, 2013", "SEP 30, 2013", "AUG 5, 2013", "JUL 11, 2013", "NOV 12, 2013", "NOV 4, 2013", "OCT 16, 2013", "OCT 14, 2013", "APR 25, 2013", "APR 16, 2013", "APR 16, 2013", "APR 15, 2013", "JUN 27, 2013", "MAR 26, 2013", "MAR 8, 2013", "FEB 14, 2013", "FEB 14, 2013", "FEB 11, 2013", "JAN 25, 2013", "JAN 23, 2013", "APR 15, 2013", "JAN 8, 2013", "DEC 27, 2012", "DEC 19, 2012", "NOV 16, 2012", "NOV 2, 2012", "OCT 23, 2012", "OCT 18, 2012", "JAN 9, 2013", "JAN 8, 2013", "DEC 27, 2012", "DEC 19, 2012", "JUL 30, 2012", "JUN 14, 2012", "MAY 4, 2012", "APR 17, 2012", "OCT 4, 2012", "SEP 18, 2012", "NOV 28, 2011", "OCT 7, 2011", "OCT 5, 2011", "JUN 7, 2011", "APR 18, 2011", "FEB 18, 2011", "APR 13, 2012", "JAN 14, 2011"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/salesforce.com-to-replace-allergan-in-sp100-2020-05-06", "https://www.nasdaq.com/articles/health-care-sector-update-for-12-26-2019%3A-hexohexo.toageacorsppi-2019-12-26", "https://www.nasdaq.com/articles/health-care-sector-update-for-12-26-2019%3A-ageacorsppi-2019-12-26", "https://www.nasdaq.com/articles/health-care-sector-update-for-12-23-2019%3A-acbacb.tosrptacor-2019-12-23", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-04-2019%3A-sdcsrptacorovid-2019-10-04", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-04-2019%3A-srptacorovid-2019-10-04", "https://www.nasdaq.com/articles/5-top-gainers-in-healthcare-sector-mnk-endp-mlnt...-2019-09-10", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-q2-2019-earnings-call-transcript-2019-08-02", "https://www.nasdaq.com/articles/salesforce.com-to-replace-allergan-in-sp100-2020-05-06", "https://www.nasdaq.com/articles/validea-joseph-piotroski-strategy-daily-upgrade-report-3232019-2019-03-23", "https://www.nasdaq.com/articles/acorda-acor-down-6-since-last-earnings-report%3A-can-it-rebound-2019-03-16", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-gains-but-lags-market%3A-what-you-should-know-2019-03-15", "https://www.nasdaq.com/articles/validea-joseph-piotroski-strategy-daily-upgrade-report-2212019-2019-02-21", "https://www.nasdaq.com/articles/acorda-therapeutics-becomes-oversold-2019-02-20", "https://www.nasdaq.com/articles/acorda-acor-q4-earnings-and-revenues-surpass-estimates-2019-02-15", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-q4-2018-earnings-conference-call-transcript-2019-02-15", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-q1-2019-earnings-call-transcript-2019-05-04", "https://www.nasdaq.com/articles/array-biopharma-arry-soars%3A-stock-adds-11-in-session-2019-02-06", "https://www.nasdaq.com/articles/is-acorda-therapeutics-acor-stock-outpacing-its-medical-peers-this-year-2019-01-31", "https://www.nasdaq.com/articles/vertex-terminates-coo-ian-smith-on-code-of-conduct-violation-2019-01-24", "https://www.nasdaq.com/articles/vertexs-orkambi-wins-eu-nod-to-treat-cystic-fibrosis-in-kids-2019-01-22", "https://www.nasdaq.com/articles/aerpio-arpo-jumps%3A-stock-rises-7.8-2019-01-22", "https://www.nasdaq.com/articles/nabriva-therapeutics-nbrv-jumps%3A-stock-rises-6.7-2019-01-15", "https://www.nasdaq.com/articles/aslans-varlitinib-fails-to-meet-endpoint-in-phase-ii-study-2019-01-14", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-tops-q4-earnings-and-revenue-estimates-2019-02-14", "https://www.nasdaq.com/articles/acorda-acor-plans-to-launch-inbrija-in-q1%3A-what-to-expect-2019-01-10", "https://www.nasdaq.com/articles/mirati-therapeutics-mrtx-catches-eye%3A-stock-jumps-5.4-2019-01-09", "https://www.nasdaq.com/articles/myriad-genetics-mygn-catches-eye%3A-stock-jumps-6.9-2019-01-07", "https://www.nasdaq.com/articles/company-news-for-dec-26-2018-2018-12-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-acor-drugs-get-fda-nod-agen-up-on-gild-deal-2018-12-26", "https://www.nasdaq.com/articles/us-stocks-move-oil-stocks-bank-stocks-mindbody-2018-12-24", "https://www.nasdaq.com/articles/health-care-sector-update-12242018-acor-cdxc-rdy-jnj-pfe-mrk-abt-amgn-2018-12-24", "https://www.nasdaq.com/articles/apellis-pharmaceuticals-apls-in-focus%3A-stock-moves-7.1-higher-2019-01-14", "https://www.nasdaq.com/articles/why-mindbody-new-gold-and-acorda-therapeutics-jumped-today-2018-12-24", "https://www.nasdaq.com/articles/health-care-sector-update-12242018-mbacorrdy-2018-12-24", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-kenneth-fisher-12162018-2018-12-16", "https://www.nasdaq.com/articles/heres-why-acorda-therapeutics-shares-sunk-15-today-2018-12-11", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-ual-algn-acor-2018-12-04", "https://www.nasdaq.com/articles/acorda-down-more-than-30-in-the-past-3-months%3A-heres-why-2018-11-15", "https://www.nasdaq.com/articles/acorda-acor-q3-earnings-top-estimates-ampyra-sales-view-up-2018-11-01", "https://www.nasdaq.com/articles/acorda-gets-fda-approval-for-parkinsons-disease-drug-inbrija-2018-12-24", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-q3-earnings-and-revenues-beat-estimates-2018-10-31", "https://www.nasdaq.com/articles/centenes-cnc-earnings-and-revenues-top-estimates-in-q3-2018-10-23", "https://www.nasdaq.com/articles/acorda-acor-stock-dips-fda-delays-decision-on-inbrija-2018-09-14", "https://www.nasdaq.com/articles/heres-why-acorda-therapeutics-falling-double-digits-today-2018-09-13", "https://www.nasdaq.com/articles/acorda-gets-unfavorable-court-ruling-for-ampyra-stock-down-2018-09-11", "https://www.nasdaq.com/articles/oversold-conditions-acorda-therapeutics-2018-09-10", "https://www.nasdaq.com/articles/acor-crosses-below-key-moving-average-level-2018-09-10", "https://www.nasdaq.com/articles/acorda-therapeutics-inc-acor-q3-2018-earnings-conference-call-transcript-2018-10-31", "https://www.nasdaq.com/articles/whats-behind-acorda-therapeutics-crashing-245-today-2018-09-10", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-alny-acor-eros-2018-09-10", "https://www.nasdaq.com/articles/acorda-acor-q2-earnings-and-revenues-surpass-estimates-2018-08-03", "https://www.nasdaq.com/articles/is-the-options-market-predicting-a-spike-in-acorda-therapeutics-acor-stock-2018-08-03", "https://www.nasdaq.com/articles/collaborations-help-alkermes-flip-profitability-2018-07-27", "https://www.nasdaq.com/articles/rsi-alert-acorda-therapeutics-acor-now-oversold-2018-07-25", "https://www.nasdaq.com/articles/whats-in-store-for-cardinal-health-cah-in-q4-earnings-2018-07-24", "https://www.nasdaq.com/articles/why-brown-forman-acorda-therapeutics-and-energy-xxi-gulf-coast-slumped-today-2018-09-10", "https://www.nasdaq.com/articles/will-hiv-sales-drive-gilead-gild-to-beat-in-q2-earnings-2018-07-20", "https://www.nasdaq.com/articles/5-biotech-stocks-well-poised-to-beat-q2-earnings-estimates-2018-07-19", "https://www.nasdaq.com/articles/implied-volatility-surging-for-acorda-acor-stock-options-2018-06-25", "https://www.nasdaq.com/articles/notable-friday-option-activity-acor-de-hrtx-2018-06-22", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-in-focus%3A-stock-moves-8.9-higher-2018-06-11", "https://www.nasdaq.com/articles/heres-why-acorda-therapeutics-rose-much-303-today-2018-06-08", "https://www.nasdaq.com/articles/acorda-acor-up-13.4-since-earnings-report%3A-can-it-continue-2018-06-01", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-vertex-vrtx-this-earnings-season-2018-07-23", "https://www.nasdaq.com/articles/will-hiv-sales-drive-gilead-gild-to-beat-in-q2-earnings-2018-07-20", "https://www.nasdaq.com/articles/5-biotech-stocks-well-poised-to-beat-q2-earnings-estimates-2018-07-19", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-acor-2018-05-24", "https://www.nasdaq.com/articles/acorda-acor-q1-earnings-miss-estimates-sales-down-y-y-2018-05-03", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-april-18th-2018-04-18", "https://www.nasdaq.com/articles/after-hours-most-active-feb-27-2018-endp-acor-intc-sppi-mdlz-frbk-2018-02-27", "https://www.nasdaq.com/articles/fda-accepts-acordas-nda-for-parkinsons-disease-candidate-2018-02-21", "https://www.nasdaq.com/articles/health-care-sector-update-05292018-aker-acor-ttoo-2018-05-29", "https://www.nasdaq.com/articles/acorda-therapeutics-joins-rank-stocks-rs-ratings-over-90-2018-02-15", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-acorda-therapeutics-acor-stock-2018-02-06", "https://www.nasdaq.com/articles/alkermes-submits-nda-for-depression-candidate-to-the-fda-2018-02-01", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-rises-8.8-2018-01-22", "https://www.nasdaq.com/articles/stocks-watch-acorda-therapeutics-sees-rs-rating-jump-84-2018-01-22", "https://www.nasdaq.com/articles/heres-why-acorda-therapeutics-inc-stock-surging-today-2018-01-19", "https://www.nasdaq.com/articles/health-care-sector-update-01192018-jnj-pfe-abt-mrk-amgn-pavm-acor-obln-agio-chek-2018-01", "https://www.nasdaq.com/articles/acorda-acor-q4-earnings-miss-estimates-revenues-beat-2018-02-16", "https://www.nasdaq.com/articles/acorda-therapeutics-joins-rank-stocks-rs-ratings-over-90-2018-02-15", "https://www.nasdaq.com/articles/acor-crosses-above-key-moving-average-level-2017-12-13", "https://www.nasdaq.com/articles/acorda-resubmits-nda-for-parkinsons-disease-candidate-inbrija-2017-12-08", "https://www.nasdaq.com/articles/parkinsons-space-in-focus-as-acorda-stops-tozadenant-trial-2017-11-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-rare-drug-gets-fda-nod-acorda-cytokinetics-hit-pipeline-setbacks", "https://www.nasdaq.com/articles/acorda-stock-up-despite-phase-iii-trial-on-tozadenant-stops-2017-11-21", "https://www.nasdaq.com/articles/pre-market-most-active-jan-19-2018-eric-qqq-tvix-ge-ibm-sq-nvda-nok-acor-gnc-wbk-uslv-2018", "https://www.nasdaq.com/articles/acorda-reports-death-in-parkinsons-trials-stock-down-40-2017-11-16", "https://www.nasdaq.com/articles/mid-day-market-update-yy-climbs-after-strong-q3-results-sandridge-energy-shares-plummet", "https://www.nasdaq.com/articles/acorda-nose-dives-5-month-low-deaths-parkinsons-studies-2017-11-15", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-target-profit-beats-estimates-2017-11-15", "https://www.nasdaq.com/articles/health-care-sector-update-11152017-mlssaphbacor-2017-11-15", "https://www.nasdaq.com/articles/mid-afternoon-market-update-oncocyte-drops-following-q3-results-sorl-auto-parts-shares", "https://www.nasdaq.com/articles/heres-why-acorda-therapeutics-got-crushed-today-2017-11-15", "https://www.nasdaq.com/articles/health-care-sector-update-11202017-acoracstacstvanth-2017-11-20", "https://www.nasdaq.com/articles/acorda-reports-death-in-parkinsons-trials-stock-down-40-2017-11-16", "https://www.nasdaq.com/articles/acorda-acor-q3-earnings-lag-estimates-revenues-up-y-y-2017-11-01", "https://www.nasdaq.com/articles/allergan-agn-to-report-q3-earnings%3A-whats-in-the-cards-2017-10-26", "https://www.nasdaq.com/articles/commit-purchase-acorda-therapeutics-17-earn-156-annualized-using-options-2017-10-23", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-acorda-therapeutics-biomarin-pharmaceutical-valeant", "https://www.nasdaq.com/articles/acorda-therapeutics-shows-market-leadership-jump-91-rs-rating-2017-10-03", "https://www.nasdaq.com/articles/health-care-sector-update-11152017-araaphbacor-2017-11-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-car-t-focus-gilead-kite-deal-incyte-baricitinib-update-2017-08-31", "https://www.nasdaq.com/articles/astrazeneca-and-takeda-ink-deal-to-develop-parkinsons-drug-2017-08-30", "https://www.nasdaq.com/articles/fdas-refusal-to-file-letter-for-inbrija-pushes-acorda-down-2017-08-30", "https://www.nasdaq.com/articles/mid-day-market-update-movado-rises-after-strong-q2-results-finish-line-shares-slide-2017", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-best-buy-tops-q2-estimates-2017-08-29", "https://www.nasdaq.com/articles/pre-market-most-active-aug-29-2017-tvix-bby-finl-qqq-acor-xiv-abco-bac-mycc-sap-baba-gsk", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2017-08-29", "https://www.nasdaq.com/articles/acorda-therapeutics-getting-closer-key-technical-measure-2017-09-26", "https://www.nasdaq.com/articles/health-care-sector-update-08292017-ctltjunoacor-2017-08-29", "https://www.nasdaq.com/articles/why-acorda-therapeutics-losing-one-quarter-its-value-today-2017-08-29", "https://www.nasdaq.com/articles/acorda-acor-q2-earnings-miss-estimates-revenues-in-line-2017-07-28", "https://www.nasdaq.com/articles/biotech-stock-roundup-cara-plunges-study-data-regulatory-updates-more-2017-07-05", "https://www.nasdaq.com/articles/acorda-files-nda-for-parkinsons-disease-candidate-inbrija-2017-06-30", "https://www.nasdaq.com/articles/wednesday-621-insider-buying-report-acor-sbbx-2017-06-21", "https://www.nasdaq.com/articles/health-care-sector-update-08292017-imgnjazzjunoacor-2017-08-29", "https://www.nasdaq.com/articles/mid-afternoon-market-update-us-stocks-turn-higher-jjill-shares-plummet-2017-08-29", "https://www.nasdaq.com/articles/why-is-acorda-acor-down-8.4-since-the-last-earnings-report-2017-06-01", "https://www.nasdaq.com/articles/biogens-fampyra-conditional-approval-converted-to-standard-2017-05-25", "https://www.nasdaq.com/articles/acorda-acor-q1-loss-wider-than-expected-revenues-miss-2017-04-28", "https://www.nasdaq.com/articles/acorda-acor-to-reduce-workforce-focus-on-product-pipeline-2017-04-06", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-down-court-ruling-patent-challenge-celg-drug-2017-04-05", "https://www.nasdaq.com/articles/mondays-etf-movers-gdxj-vioo-2017-04-03", "https://www.nasdaq.com/articles/health-care-sector-update-06092017-acor-2017-06-09", "https://www.nasdaq.com/articles/acorda-presents-phase-iii-data-on-pd-candidate-cvt-301-2017-06-07", "https://www.nasdaq.com/articles/why-is-acorda-acor-down-8.4-since-the-last-earnings-report-2017-06-01", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-amba-acor-cc-2017-03-31", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-drops-50-points-trc-companies-shares-spike-higher-2017-03", "https://www.nasdaq.com/articles/acorda-presents-data-for-parkinsons-candidate-cvt-301-2017-03-30", "https://www.nasdaq.com/articles/why-is-acorda-acor-up-10.6-since-the-last-earnings-report-2017-03-17", "https://www.nasdaq.com/articles/acordas-acor-ms-drug-patents-invalidated-shares-plunge-2017-04-03", "https://www.nasdaq.com/articles/why-acorda-therapeutics-inc-plummeted-second-straight-day-2017-04-03", "https://www.nasdaq.com/articles/acordas-four-ampyra-patents-upheld-by-ptab-shares-rise-2017-03-13", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-adds-6.5-in-session-2017-03-10", "https://www.nasdaq.com/articles/implied-volatility-surging-for-acorda-therapeutics-acor-stock-options-2017-02-23", "https://www.nasdaq.com/articles/acorda-acor-reports-narrower-than-expected-loss-in-q4-2017-02-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-regenerons-praluent-remain-market-now-gild-presents-hiv-data-2017-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-incyte-prothena-acorda-therapeutics-and-axovant", "https://www.nasdaq.com/articles/alkermes-starts-phase-iii-study-to-treat-multiple-sclerosis-2017-03-17", "https://www.nasdaq.com/articles/perrigo-company-prgo-q4-earnings%3A-disappointment-in-store-2017-02-10", "https://www.nasdaq.com/articles/acorda-acor-catches-eye%3A-stock-gains-20.8-in-session-2017-02-10", "https://www.nasdaq.com/articles/alexion-alxn-q4-earnings%3A-can-the-stock-pull-a-surprise-2017-02-10", "https://www.nasdaq.com/articles/why-acorda-therapeutics-stock-jumping-today-2017-02-09", "https://www.nasdaq.com/articles/thursdays-etf-movers-xbi-gdx-2017-02-09", "https://www.nasdaq.com/articles/teva-teva-q4-earnings%3A-whats-in-store-for-the-stock-2017-02-08", "https://www.nasdaq.com/articles/can-prothena-prta-pull-a-surprise-this-earnings-season-2017-02-08", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q4-earnings%3A-whats-in-store-2017-02-10", "https://www.nasdaq.com/articles/can-humana-hum-pull-a-surprise-this-earnings-season-2017-02-06", "https://www.nasdaq.com/articles/gilead-sciences-gild-q4-earnings%3A-whats-in-the-cards-2017-02-03", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph-q1-earnings%3A-whats-in-store-2017-02-02", "https://www.nasdaq.com/articles/implied-volatility-surging-for-acorda-therapeutics-acor-stock-options-2017-02-02", "https://www.nasdaq.com/articles/allergan-agn-q4-earnings%3A-whats-in-store-for-the-stock-2017-02-02", "https://www.nasdaq.com/articles/glaxosmithkline-gsk-q4-earnings%3A-whats-in-the-cards-2017-02-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-redhill-biopharma-cempra-vertex-pharmaceuticals-acorda", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-acor-aap-sbac-2017-02-08", "https://www.nasdaq.com/articles/kura-oncology-starts-dosing-patients-in-phase-ii-cmml-study-2017-01-18", "https://www.nasdaq.com/articles/whats-behind-clovis-clvs-one-year-rally-of-146.3-2017-01-17", "https://www.nasdaq.com/articles/acorda-stops-post-stroke-development-program-on-ampyra-2016-11-22", "https://www.nasdaq.com/articles/why-acorda-therapeutics-stock-slumping-today-2016-11-21", "https://www.nasdaq.com/articles/mid-day-market-update-headwaters-surges-acquisition-news-cubic-shares-slide-2016-11-21", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-symantec-acquire-lifelock-2016-11-21", "https://www.nasdaq.com/articles/health-care-sector-update-11212016-mnkogenacor-2016-11-21", "https://www.nasdaq.com/articles/will-these-5-drug-stocks-be-big-winners-q4-earnings-season-2017-01-24", "https://www.nasdaq.com/articles/kura-oncology-starts-dosing-patients-in-phase-ii-cmml-study-2017-01-18", "https://www.nasdaq.com/articles/acorda-acor-reports-wider-q3-loss-revenues-down-y-y-2016-10-28", "https://www.nasdaq.com/articles/oversold-conditions-acorda-therapeutics-2016-10-27", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-33-chemtura-shares-surge-following-acquisition-news-2016", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-cal-maine-posts-wider-expected-loss-2016-09", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-falls-150-points-himax-technologies-shares-slide-after", "https://www.nasdaq.com/articles/health-care-sector-update-11212016-imucogenacor-2016-11-21", "https://www.nasdaq.com/articles/health-care-sector-update-08262016-ptlatgtxacor-2016-08-26", "https://www.nasdaq.com/articles/notable-thursday-option-activity-acor-pg-sfl-2016-08-25", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-acor-sq-agn-2016-08-03", "https://www.nasdaq.com/articles/how-parts-add-pbe-headed-52-2016-08-02", "https://www.nasdaq.com/articles/health-care-sector-update-07282016-jnj-pfe-abt-mrk-amgn-acor-bmy-2016-07-28", "https://www.nasdaq.com/articles/anavexs-lead-candidate-gets-orphan-drug-status-yet-again-2016-06-23", "https://www.nasdaq.com/articles/fates-fate-protmune-gets-fast-track-status-stock-up-2016-06-21", "https://www.nasdaq.com/articles/health-care-sector-update-08262016-alrabttgtxacor-2016-08-26", "https://www.nasdaq.com/articles/health-care-sector-update-08262016-ptlatgtxacor-2016-08-26", "https://www.nasdaq.com/articles/notable-thursday-option-activity-acor-pg-sfl-2016-08-25", "https://www.nasdaq.com/articles/forget-biogen-biib-buy-these-5-biotech-stocks-instead-2016-06-08", "https://www.nasdaq.com/articles/celldex-cldx-presents-phase-ii-melanoma-study-data-2016-06-06", "https://www.nasdaq.com/articles/the-medicines-co.-carbavance-tango-1-study-enrolled-2016-05-27", "https://www.nasdaq.com/articles/alkermes-begins-phase-i-study-on-immuno-oncology-drug-2016-05-26", "https://www.nasdaq.com/articles/first-week-august-19th-options-trading-acorda-therapeutics-acor-2016-06-21", "https://www.nasdaq.com/articles/acorda-shelves-development-epilepsy-treatment-plumiaz-2016-05-23", "https://www.nasdaq.com/articles/aegerion-enters-into-settlement-agreement-with-doj-and-sec-2016-05-13", "https://www.nasdaq.com/articles/drug-stocks-q1-earnings-slated-on-may-11%3A-acrs-ears-more-2016-05-10", "https://www.nasdaq.com/articles/vivus-vvus-q1-loss-narrower-qsymia-sales-decline-2016-05-04", "https://www.nasdaq.com/articles/acorda-acor-q1-earnings-decline-yy-ampyra-focus-2016-04-29", "https://www.nasdaq.com/articles/analysts-see-10-gains-ahead-holdings-ijt-2016-04-26", "https://www.nasdaq.com/articles/seth-klarman-profits-biotie-therapies-buyout-2016-04-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-xenoport-soars-acquisition-deal-abbvie-crohns-disease-drug-fares", "https://www.nasdaq.com/articles/acorda-gets-favorable-court-ruling-in-ampyra-patent-lawsuit-2016-03-22", "https://www.nasdaq.com/articles/why-petroleo-brasileiro-sa-petrobras-adr-pbr-acorda-therapeutics-inc-acor-and", "https://www.nasdaq.com/articles/acorda-therapeutics-stock-slumped-february-it-now-bargain-2016-03-14", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-shares-cross-above-200-dma-2016-03-02", "https://www.nasdaq.com/articles/ijts-underlying-holdings-imply-20-gain-potential-2016-02-22", "https://www.nasdaq.com/articles/acorda-q4-earnings-decline-yy-ampyra-pipeline-focus-2016-02-12", "https://www.nasdaq.com/articles/why-acorda-therapeutics-acor-might-surprise-this-earnings-season-2016-02-10", "https://www.nasdaq.com/articles/why-acorda-therapeutics-stock-sank-229-march-2016-04-12", "https://www.nasdaq.com/articles/acorda-gets-favorable-court-ruling-in-ampyra-patent-lawsuit-2016-03-22", "https://www.nasdaq.com/articles/why-petroleo-brasileiro-sa-petrobras-adr-pbr-acorda-therapeutics-inc-acor-and", "https://www.nasdaq.com/articles/acorda-therapeutics-stock-slumped-february-it-now-bargain-2016-03-14", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-shares-cross-above-200-dma-2016-03-02", "https://www.nasdaq.com/articles/will-amgen-amgn-continue-earnings-streak-q4-2016-01-26", "https://www.nasdaq.com/articles/will-lilly-lly-keep-earnings-streak-alive-q4-2016-01-26", "https://www.nasdaq.com/articles/allergans-botox-gains-fda-nod-for-lower-limb-spasticity-2016-01-26", "https://www.nasdaq.com/articles/will-teva-teva-continue-its-earnings-streak-q4-2016-02-10", "https://www.nasdaq.com/articles/will-higher-expenses-hurt-vertexs-vrtx-4q-earnings-2016-01-25", "https://www.nasdaq.com/articles/what-makes-incyte-incy-a-strong-sell-2016-01-20", "https://www.nasdaq.com/articles/biotie-therapies-biti-catches-eye%3A-stock-moves-up-86.5-2016-01-20", "https://www.nasdaq.com/articles/jj-plans-to-cut-3000-medical-devices-jobs-2015-view-intact-2016-01-20", "https://www.nasdaq.com/articles/biotie-therapies-soars-on-%24363m-buyout-deal-with-acorda-2016-01-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-sarepta-plunges-briefing-documents-acorda-buy-biotie-2016-01-20", "https://www.nasdaq.com/articles/mid-day-market-update-dow-surges-150-points-progressive-waste-shares-spike-higher-2016-01", "https://www.nasdaq.com/articles/will-biogen-biib-beat-4q-earnings-ms-franchise-sales-2016-01-25", "https://www.nasdaq.com/articles/closing-update-dow-sp-500-hang-narrow-gains-nasdaq-struggles-energy-mining-stocks-slump", "https://www.nasdaq.com/articles/eleven-biotherapeutics-eye-drug-fails-in-phase-iii-study-2016-01-19", "https://www.nasdaq.com/articles/health-care-sector-update-01192016-bitiacoraezsaeztoebio-2016-01-19", "https://www.nasdaq.com/articles/mid-afternoon-market-update-us-stocks-turn-red-crude-oil-falls-over-3-2016-01-19", "https://www.nasdaq.com/articles/sarepta-tanks-eteplirsen-briefing-document-raises-concerns-2016-01-18", "https://www.nasdaq.com/articles/is-acorda-therapeutics-acor-a-great-growth-stock-2016-01-15", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-vrtx-jumps%3A-stock-moves-up-5.8-2016-01-15", "https://www.nasdaq.com/articles/heres-why-biotie-therapies-corps-stock-skyrocketed-today-2016-01-19", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-january-13th-2016-01-13", "https://www.nasdaq.com/articles/sangamo-biosciences-sgmo-worth-a-look%3A-stock-up-9.2-2016-01-13", "https://www.nasdaq.com/articles/arena-boehringer-ingelheim-ink-deal-schizophrenia-in-focus-2016-01-13", "https://www.nasdaq.com/articles/acordas-ampyra-ends-2015-strong-note-pipeline-focus-2016-01-12", "https://www.nasdaq.com/articles/health-care-sector-update-12032015-fomx-acor-psti-2015-12-03", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-priority-review-from-the-fda-2015-11-17", "https://www.nasdaq.com/articles/why-acorda-therapeutics-acor-could-be-positioned-for-a-surge-2015-11-06", "https://www.nasdaq.com/articles/geron-up-myelodysplastic-syndromes-phase-ii-iii-study-begins-2016-01-15", "https://www.nasdaq.com/articles/vertex-vrtx-posts-narrower-q3-loss-ups-kalydeco-view-2015-10-29", "https://www.nasdaq.com/articles/acorda-up-on-q3-earnings-revenue-beat-ampyra-in-focus-2015-10-23", "https://www.nasdaq.com/articles/acorda-therapeutics-breaks-above-200-day-moving-average-bullish-acor-2015-10-22", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-regeneron-acorda-amicus-and-abbvie-2015-10-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-pbm-lists-both-amgen-regeneron-pcsk9-inhibitors-fold-plunges-nda", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-moves-up-12-2015-10-06", "https://www.nasdaq.com/articles/acorda-soars-settles-ampyra-patent-dispute-with-allergan-2015-10-06", "https://www.nasdaq.com/articles/looking-for-a-top-momentum-stock-3-reasons-why-acorda-therapeutics-acor-is-a-great-choice", "https://www.nasdaq.com/articles/after-hours-most-active-oct-1-2015-hlx-mu-caa-rmbs-qqq-ete-sune-msft-acor-csco-pfe-rad", "https://www.nasdaq.com/articles/3-biotech-stocks-bucking-stock-market-crash-2015-08-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-vital-therapies-amgen-biomarin-acorda-and-macrocure", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-moves-8.3-higher-2015-08-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-gains-patent-issues-vital-crushed-liver-data-2015-08-26", "https://www.nasdaq.com/articles/why-acorda-therapeutics-inc-stock-surged-higher-today-2015-08-25", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-best-buy-tops-q2-views-2015-08-25", "https://www.nasdaq.com/articles/why-acorda-therapeutics-soaring-12-today-2015-10-05", "https://www.nasdaq.com/articles/oversold-conditions-acorda-therapeutics-acor-2015-08-20", "https://www.nasdaq.com/articles/acorda-2q-earnings-revenues-top-ampyra-focus-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/did-researchers-just-unlock-secret-fighting-parkinsons-disease-2015-07-18", "https://www.nasdaq.com/articles/8-biotech-stocks-buy-2015-07-16", "https://www.nasdaq.com/articles/acor-crosses-above-key-moving-average-level-2015-07-14", "https://www.nasdaq.com/articles/bayer-files-hemophilia-a-drug-marketing-application-in-japan-analyst-blog-2015-07-01", "https://www.nasdaq.com/articles/amag-down-on-cord-blood-registry-deal-for-%24700-million-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/acorda-acor-gets-favorable-outcome-in-ampyra-ipr-issue-2015-08-25", "https://www.nasdaq.com/articles/alexions-strensiq-and-kanuma-get-positive-chmp-opinions-analyst-blog-2015-06-29", "https://www.nasdaq.com/articles/bristol-myers-announces-job-cuts-changes-in-rd-sites-analyst-blog-2015-06-26", "https://www.nasdaq.com/articles/catalyst-pharmaceuticals-reports-tourettes-disorder-data-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/bayer-contraceptive-essure-to-face-fda-panel-on-complaints-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/mckesson-keeps-fy16-earnings-view-acquisitions-hold-key-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/synta-reports-encouraging-preclinical-data-on-ganetespib-analyst-blog-2015-06-24", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-schizophrenia-drug-shows-success-analyst-blog-2015-06-24", "https://www.nasdaq.com/articles/regeneron-bayers-eylea-gets-label-expansion-in-japan-analyst-blog-2015-06-29", "https://www.nasdaq.com/articles/vicals-genital-herpes-vaccine-fails-in-phase-i-ii-study-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-spinal-muscular-atrophy-data-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/epizyme-lead-candidate-effective-in-ongoing-cancer-study-analyst-blog-2015-06-22", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-acor-2015-06-22", "https://www.nasdaq.com/articles/acorda-gains-on-positive-parkinsons-disease-study-data-analyst-blog-2015-06-17", "https://www.nasdaq.com/articles/bayer-bayry-up-on-deal-to-sell-diabetes-care-business-analyst-blog-2015-06-11", "https://www.nasdaq.com/articles/novo-nordisk-reveals-new-findings-from-additional-studies-analyst-blog-2015-06-08", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-shares-march-higher-can-it-continue-tale-of-the-tape-2015-06-23", "https://www.nasdaq.com/articles/gilead-reveals-encouraging-data-from-leukemia-study-analyst-blog-2015-06-01", "https://www.nasdaq.com/articles/aegerions-juxtapid-successful-in-phase-iii-japanese-study-analyst-blog-2015-05-27", "https://www.nasdaq.com/articles/actavis-continue-selling-namenda-ir-under-court-ruling-analyst-blog-2015-05-26", "https://www.nasdaq.com/articles/xbiotechs-xilonix-recommended-for-colorectal-cancer-study-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/alnylam-files-clinical-trial-application-for-aln-aat-analyst-blog-2015-05-18", "https://www.nasdaq.com/articles/parkinsons-biotech-cynapsus-therapeutics-files-60-million-us-ipo-2015-05-16", "https://www.nasdaq.com/articles/teva-presents-encouraging-data-from-chronic-migraine-study-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/ultragenyx-krn23-positive-in-children-to-be-studied-in-adults-analyst-blog-2015-06-03", "https://www.nasdaq.com/articles/sanofi-sny-exercises-celiac-disease-program-option-analyst-blog-2015-05-14", "https://www.nasdaq.com/articles/inovio-narrows-q1-loss-y-y-misses-earnings-estimates-analyst-blog-2015-05-12", "https://www.nasdaq.com/articles/acorda-posts-1q-loss-ampyra-generic-challenges-focus-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/will-united-therapeutics-uthr-miss-this-earnings-season-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/will-hospira-hsp-earnings-surprise-estimates-in-q1-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-earnings-streak-continue-in-q1-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/acorda-reports-encouraging-data-on-ms-drug-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/eli-lilly-sanford-burnham-ink-deal-for-immunotherapies-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/sanofi-sny-exercises-celiac-disease-program-option-analyst-blog-2015-05-14", "https://www.nasdaq.com/articles/inovio-narrows-q1-loss-y-y-misses-earnings-estimates-analyst-blog-2015-05-12", "https://www.nasdaq.com/articles/acorda-posts-1q-loss-ampyra-generic-challenges-focus-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/will-united-therapeutics-uthr-miss-this-earnings-season-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/will-hospira-hsp-earnings-surprise-estimates-in-q1-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-earnings-streak-continue-in-q1-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/horizon-pharmas-actimmune-gets-fast-track-status-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/new-hedge-fund-strategy-just-might-be-crazy-enough-work-2015-04-19", "https://www.nasdaq.com/articles/ocular-therapeutix-slumps-19-after-negative-study-data-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/hospira-slammed-with-another-warning-letter-by-the-fda-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/alkermes-reports-encouraging-data-on-schizophrenia-drug-analyst-blog-2015-04-07", "https://www.nasdaq.com/articles/repros-gets-eu-update-on-secondary-hypogonadism-drug-analyst-blog-2015-04-07", "https://www.nasdaq.com/articles/teva-xenon-start-phase-ii-postherpetic-neuralgia-study-analyst-blog-2015-04-06", "https://www.nasdaq.com/articles/repros-secondary-hypogonadism-drug-under-fda-review-analyst-blog-2015-04-02", "https://www.nasdaq.com/articles/cambrex-cbm-looks-good%3A-stock-adds-11.6-in-session-tale-of-the-tape-2015-04-01", "https://www.nasdaq.com/articles/gilead-submits-regulatory-application-for-hiv-drug-in-u.s.-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/what-makes-novavax-nvax-a-strong-sell-tale-of-the-tape-2015-03-31", "https://www.nasdaq.com/articles/biodelivery-sciences-international-bdsi-crumbles%3A-stock-falls-24.3-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/amgens-kyprolis-gets-fda-priority-review-for-expanded-use-analyst-blog-2015-03-31", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-achillion-pharmaceuticals-achn-tale", "https://www.nasdaq.com/articles/proteon-up-on-positive-long-term-data-on-its-candidate-analyst-blog-2015-03-30", "https://www.nasdaq.com/articles/avalanche-biotechnologies-aavl-crumbles%3A-stock-falls-by-6.4-tale-of-the-tape-2015-03-27", "https://www.nasdaq.com/articles/orexigens-obesity-drug-mysimba-gains-european-approval-analyst-blog-2015-03-27", "https://www.nasdaq.com/articles/raptor-pharmaceuticals-rptp-in-focus%3A-stock-falls-9.7-tale-of-the-tape-2015-04-01", "https://www.nasdaq.com/articles/sanofi-reveals-cerdelga-data-fda-oks-quadracel-vaccine-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-hsbc-holdings-goldman-sachs-acorda-therapeutics-biogen", "https://www.nasdaq.com/articles/ovascience-inc.-ovas-in-focus%3A-stock-surges-12.2-tale-of-the-tape-2015-03-25", "https://www.nasdaq.com/articles/coronado-biosciences-inc.-cndo-in-focus%3A-stock-jumps-8.6-tale-of-the-tape-2015-03-25", "https://www.nasdaq.com/articles/weakness-seen-in-five-prime-therapeutics-fprx-estimates%3A-should-you-stay-away-tale-of-the", "https://www.nasdaq.com/articles/2-stocks-to-beat-the-dollars-volatile-run-analyst-blog-2015-03-24", "https://www.nasdaq.com/articles/vertex-falls-on-disappointing-kalydecovx-661-combo-data-analyst-blog-2015-03-24", "https://www.nasdaq.com/articles/merck-in-%2410b-buyback-keytruda-tops-melanoma-study-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/sanofi-reveals-cerdelga-data-fda-oks-quadracel-vaccine-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-hsbc-holdings-goldman-sachs-acorda-therapeutics-biogen", "https://www.nasdaq.com/articles/ovascience-inc.-ovas-in-focus%3A-stock-surges-12.2-tale-of-the-tape-2015-03-25", "https://www.nasdaq.com/articles/coronado-biosciences-inc.-cndo-in-focus%3A-stock-jumps-8.6-tale-of-the-tape-2015-03-25", "https://www.nasdaq.com/articles/weakness-seen-in-five-prime-therapeutics-fprx-estimates%3A-should-you-stay-away-tale-of-the", "https://www.nasdaq.com/articles/2-stocks-to-beat-the-dollars-volatile-run-analyst-blog-2015-03-24", "https://www.nasdaq.com/articles/sanofi-inks-multi-component-strategic-deal-with-evotec-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/aeterna-zentaris-inc.-aezs-in-focus%3A-stock-jumps-5.3-tale-of-the-tape-2015-03-23", "https://www.nasdaq.com/articles/amicus-therapeutics-slumps%3A-fold-falls-6.8-in-session-tale-of-the-tape-2015-03-23", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-crumbles%3A-stock-falls-by-6.4-tale-of-the-tape-2015-03-23", "https://www.nasdaq.com/articles/biogen-gains-on-positive-alzheimers-drug-interim-results-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/celgene-presents-efficacy-safety-data-on-otezla-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/pfizer-reveals-detailed-xeljanz-data-from-psoriasis-study-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-inc.-ino-jumps%3A-stock-rises-12.8-tale-of-the-tape-2015-03-20", "https://www.nasdaq.com/articles/sanofi-inks-multi-component-strategic-deal-with-evotec-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/dbv-technologies-dbvt-jumps%3A-stock-up-7.2-in-session-tale-of-the-tape-2015-03-19", "https://www.nasdaq.com/articles/regeneron-sanofis-pcsk9-drug-praluent-data-published-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/amgen-presents-encouraging-pcsk9-inhibitor-repatha-data-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/mercks-sugammadex-faces-setback-fda-delays-meeting-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/alnylam-announces-positive-data-from-natural-history-study-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/trovagene-trov-posts-wider-q4-loss-on-higher-expenses-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/geron-corporation-gern-jumps%3A-stock-rises-5.6-tale-of-the-tape-2015-03-13", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-thursday-tale-of-the-tape-2015-03-12", "https://www.nasdaq.com/articles/eleven-biotherapeutics-ebio-crumbles%3A-stock-falls-by-5.6-tale-of-the-tape-2015-03-17", "https://www.nasdaq.com/articles/regeneron-sanofis-pcsk9-drug-praluent-data-published-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/amgen-presents-encouraging-pcsk9-inhibitor-repatha-data-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/will-kite-pharma-kite-disappoint-this-earnings-season-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-tumbles%3A-stock-goes-down-9.7-tale-of-the-tape-2015-02-11", "https://www.nasdaq.com/articles/will-hospira-hsp-miss-q4-earnings-on-low-precedex-sales-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-acorda-therapeutics-acor-tale-of-the-tape-2015-02", "https://www.nasdaq.com/articles/relative-strength-alert-acorda-therapeutics-2015-02-27", "https://www.nasdaq.com/articles/will-regeneron-regn-beat-q4-earnings-on-eylea-sales-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/will-avalanche-aavl-miss-this-earnings-on-higher-costs-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/will-zoetis-zts-earnings-disappoint-expectation-in-q4-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/will-perrigo-prgo-disappoint-this-earnings-season-analyst-blog-2015-02-03", "https://www.nasdaq.com/articles/will-teva-teva-earnings-surprise-on-higher-sales-analyst-blog-2015-02-03", "https://www.nasdaq.com/articles/will-glaxo-gsk-q4-earnings-suffer-from-lower-revenues-analyst-blog-2015-02-02", "https://www.nasdaq.com/articles/will-gilead-gild-miss-q4-earnings-on-low-hcv-drug-sales-analyst-blog-2015-02-02", "https://www.nasdaq.com/articles/davita-healthcare-dva%3A-whats-in-store-for-q4-earnings-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/will-mercks-mrk-q4-earnings-be-hit-by-patent-expiries-analyst-blog-2015-02-02", "https://www.nasdaq.com/articles/will-generics-continue-to-hit-eli-lillys-lly-q4-earnings-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/abbvie-abbv-set-beat-4q-earnings-humira-sales-analyst-blog-2015-01-28", "https://www.nasdaq.com/articles/will-biogen-biib-surpass-q4-earnings-expectations-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/will-vertex-vrtx-surprise-lower-loss-q4-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/first-week-march-20th-options-trading-acorda-therapeutics-acor-2015-01-23", "https://www.nasdaq.com/articles/closing-update-late-bounce-carries-stocks-second-positive-day-row-tech-shares-pace-advance", "https://www.nasdaq.com/articles/will-allergan-agn-disappoint-on-earnings-this-quarter-analyst-blog-2015-02-02", "https://www.nasdaq.com/articles/strength-seen-in-alliqua-alqa%3A-stock-up-13.2-in-session-tale-of-the-tape-2014-12-30", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-tuesday-tale-of-the-tape-2014-12-30", "https://www.nasdaq.com/articles/amag-takeda-mutually-end-agreement-for-feraheme-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/biomarins-vimizim-okd-in-japan-for-morquio-a-syndrome-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/cyberonics%3A-vns-therapy-strong-reimbursement-woes-stay-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/qiagen-poised-on-molecular-diagnostics-international-strength-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/3-companies-growing-faster-mannkind-corporation-2014-12-17", "https://www.nasdaq.com/articles/health-care-sector-update-01202015-vbltacorblrxpetsmdwd-2015-01-20", "https://www.nasdaq.com/articles/is-acorda-therapeutics-acor-stock-a-solid-choice-right-now-tale-of-the-tape-2014-12-01", "https://www.nasdaq.com/articles/acor-crosses-below-key-moving-average-level-2014-11-14", "https://www.nasdaq.com/articles/alkermes-incurs-wider-q3-loss-but-revenues-grow-y-y-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/acorda-acor-beats-q3-earnings-ups-ampyra-outlook-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/5-best-biotech-stocks-buy-now-2014-10-21", "https://www.nasdaq.com/articles/acorda-skyrockets-on-%24525m-civitas-therapeutics-deal-analyst-blog-2014-09-25", "https://www.nasdaq.com/articles/acor-makes-bullish-cross-above-critical-moving-average-2014-09-24", "https://www.nasdaq.com/articles/acordas-ampyra-in-phase-iii-for-post-stroke-walking-deficit-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-24-0", "https://www.nasdaq.com/articles/sector-update-health-care-shares-flat-pre-market-2014-09-24", "https://www.nasdaq.com/articles/pre-market-most-active-sep-24-2014-aapl-gsk-mack-avnr-san-baba-acor-siri-tvix-nok-bac-azn", "https://www.nasdaq.com/articles/dow-jumps-170-points-bed-bath-beyond-shares-rise-upbeat-results-2014-09-24", "https://www.nasdaq.com/articles/wednesday-sector-leaders-drugs-biotechnology-stocks-2014-09-24", "https://www.nasdaq.com/articles/wednesdays-etf-movers-xbi-gdxj-2014-09-24", "https://www.nasdaq.com/articles/us-stocks-rise-accenture-shares-decline-weak-forecast-2014-09-24", "https://www.nasdaq.com/articles/markets-edge-lower-kb-home-posts-downbeat-results-2014-09-24", "https://www.nasdaq.com/articles/acorda-beats-q2-earnings-revenues-maintains-view-analyst-blog-2014-08-04", "https://www.nasdaq.com/articles/will-teva-pharmaceutical-teva-beat-q2-earnings-estimates-analyst-blog-2014-07-30", "https://www.nasdaq.com/articles/healthcare-spending-uptrend%3A-3-medical-stocks-for-strong-growth-analyst-blog-2014-07-23", "https://www.nasdaq.com/articles/markets-edge-higher-alcoa-profit-beats-street-view-2014-07-09", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-acorda-could-file-patent-infringement-suit", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-06-26-1", "https://www.nasdaq.com/articles/acor-makes-notable-cross-below-critical-moving-average-2014-06-25", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-acor-2014-08-26", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-06-18", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-in-focus%3A-stock-tumbles-9-tale-of-the-tape-2014-06-18", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-pfizer-teams-cellectis-immunotherapy-2014", "https://www.nasdaq.com/articles/mid-day-market-update-amira-rises-upbeat-earnings-acorda-therapeutics-shares-tumble-2014", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-gain-factset-posts-rise-revenue-2014-06-17", "https://www.nasdaq.com/articles/mid-afternoon-market-update-oil-falls-us-indexes-rise-afternoon-session-2014-06-17", "https://www.nasdaq.com/articles/first-week-january-2015-options-trading-acorda-therapeutics-acor-2014-05-20", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-in-focus%3A-stock-moves-7.8-higher-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/acorda-down-on-plumiaz-crl-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/next-chapter-acorda-story-will-be-page-turner-2014-04-10", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-rises-7.5-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/acorda-up-after-q4-earnings-analyst-blog-2014-02-18", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-02-13-0", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-fairly-flat-acorda-q4-earnings-top-street-view-2014-02-13", "https://www.nasdaq.com/articles/will-zoetis-zts-miss-estimates-in-q4-analyst-blog-2014-02-10", "https://www.nasdaq.com/articles/acorda-misses-on-earnings-beats-revs-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/acor-preliminary-q4-revs-look-good-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/positive-data-on-incytes-jakafi-analyst-blog-2013-12-10", "https://www.nasdaq.com/articles/another-rd-failure-for-eli-lilly-analyst-blog-2013-12-06", "https://www.nasdaq.com/articles/mdco-acquires-rempex-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/biodelivery-sciences-bdsi-in-focus%3A-stock-adds-10.9-in-session-tale-of-the-tape-2013-12-04", "https://www.nasdaq.com/articles/biogens-hemophilia-b-drug-approval-delayed-analyst-blog-2013-12-03", "https://www.nasdaq.com/articles/dendreon-narrows-loss-provenge-disappoints-again-analyst-blog-2013-11-15", "https://www.nasdaq.com/articles/acorda-therapeutics-inc-acor-new-analyst-report-zacks-equity-research-zacks-equity", "https://www.nasdaq.com/articles/acorda-down-on-q3-earnings-analyst-blog-2013-11-04", "https://www.nasdaq.com/articles/acordas-label-expansion-efforts-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/acordas-ggf2-in-another-study-analyst-blog-2013-10-14", "https://www.nasdaq.com/articles/biotech-stocks-continue-recent-downtrend-ariad-tumbles-lowest-price-nearly-three-years", "https://www.nasdaq.com/articles/acorda-progresses-with-pipeline-analyst-blog-2013-09-30", "https://www.nasdaq.com/articles/acorda-misses-on-earnings-by-a-penny-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/acorda-expands-pipeline-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/chelsea-therapeutics-chtp-worth-watching%3A-stock-surges-11-tale-of-the-tape-2013-11-12", "https://www.nasdaq.com/articles/acorda-down-on-q3-earnings-analyst-blog-2013-11-04", "https://www.nasdaq.com/articles/acordas-label-expansion-efforts-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/acordas-ggf2-in-another-study-analyst-blog-2013-10-14", "https://www.nasdaq.com/articles/acorda-initiates-study-on-rhigm22-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/biotech-alkermes-poised-swell-pipeline-wins-2013-04-16", "https://www.nasdaq.com/articles/market-wrap-tuesday-april-16-stock-market-rebounds-strongly-mondays-sharp-losses-2013-04", "https://www.nasdaq.com/articles/mid-afternoon-market-update-explosions-rock-downtown-boston-authorities-unsure-if", "https://www.nasdaq.com/articles/data-on-acorda-pipeline-candidate-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/acorda-reports-data-on-epilepsy-drug-analyst-blog-2013-03-26", "https://www.nasdaq.com/articles/acorda-presents-ggf2-data-analyst-blog-2013-03-08", "https://www.nasdaq.com/articles/earnings-miss-at-acorda-analyst-blog-2013-02-14", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-thursday-tale-of-the-tape-2013-02-14", "https://www.nasdaq.com/articles/acorda-presents-encouraging-data-analyst-blog-2013-02-11", "https://www.nasdaq.com/articles/acorda-gets-us-army-support-analyst-blog-2013-01-25", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-wednesday-tale-of-the-tape-2013-01-23", "https://www.nasdaq.com/articles/mid-day-market-update-sprint-surges-dish-network-offer-aurico-gold-tumbles-2013-04-15", "https://www.nasdaq.com/articles/acorda-provides-guidance-analyst-blog-2013-01-08", "https://www.nasdaq.com/articles/acorda-completes-acquisition-of-neuronex-analyst-blog-2012-12-27", "https://www.nasdaq.com/articles/celgene-sutro-join-forces-analyst-blog-2012-12-19", "https://www.nasdaq.com/articles/alkermes-reverts-to-neutral-analyst-blog-2012-11-16", "https://www.nasdaq.com/articles/acorda-beats-on-all-fronts-analyst-blog-2012-11-02", "https://www.nasdaq.com/articles/acordas-ampyra-patent-extended-analyst-blog-2012-10-23", "https://www.nasdaq.com/articles/acorda-initiated-at-neutral-analyst-blog-2012-10-18", "https://www.nasdaq.com/articles/alkermes-maintains-fiscal-2013-view-analyst-blog-2013-01-09", "https://www.nasdaq.com/articles/acorda-provides-guidance-analyst-blog-2013-01-08", "https://www.nasdaq.com/articles/acorda-completes-acquisition-of-neuronex-analyst-blog-2012-12-27", "https://www.nasdaq.com/articles/celgene-sutro-join-forces-analyst-blog-2012-12-19", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-31-2012-bp-adm-aet-amg-wtr-brkr-avx-auxl-acor-allt-cplp", "https://www.nasdaq.com/articles/acorda-commences-patient-enrollment-analyst-blog-2012-06-14", "https://www.nasdaq.com/articles/revenues-climb-at-acorda-analyst-blog-2012-05-04", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2012-04-17", "https://www.nasdaq.com/articles/after-hours-most-active-oct-4-2012-sun-petm-amat-qqq-cab-acor-nvda-bac-orcl-nok-hpq-2012", "https://www.nasdaq.com/articles/back-to-neutral-on-alkermes-analyst-blog-2012-09-18", "https://www.nasdaq.com/articles/big-potential-takeover-targets-solid-profitability-2011-11-28", "https://www.nasdaq.com/articles/top-10-list-unusual-option-activity-2011-10-07", "https://www.nasdaq.com/articles/brain-disorders-3-biotech-stocks-forefront-2011-10-05", "https://www.nasdaq.com/articles/options-ideas-24-healthcare-stocks-bullish-options-sentiment-2011-06-07", "https://www.nasdaq.com/articles/put-sellers-show-confidence-acorda-2011-04-18", "https://www.nasdaq.com/articles/how-play-biotech-etfs-2011-02-18", "https://www.nasdaq.com/articles/biogens-fampyra-launched-in-canada-analyst-blog-2012-04-13", "https://www.nasdaq.com/articles/top-20-most-undervalued-healthcare-stocks-target-price-2011-01-14"], "Content": []}